Risk-Benefit Assessment in Research Protocols
Systematic Evaluation of Research Risks and Benefits for Ethics Review · Also known as: risk-benefit analysis, risk-benefit calculation, risk-benefit justification, harm-benefit ratio
A risk-benefit assessment is a systematic evaluation of the potential harms and benefits of a proposed research study, documented in ethics committee applications. The Belmont Report (1979) established the principle of beneficence—maximizing benefits while minimizing harm—as a cornerstone of research ethics. Regulatory frameworks (45 CFR 46.111 in the U.S., equivalent in other jurisdictions) require ethics committees to determine that risks are reasonable in relation to anticipated benefits before approving research. This assessment is not a simple calculation (risks + benefits) but a qualitative judgment incorporating probability, magnitude, and distribution of harms and benefits.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
Include a formal risk-benefit assessment in every ethics application involving human subjects research. The assessment is mandatory in regulations and should not be omitted or relegated to a brief sentence. Use this method when: (1) you are submitting a research protocol to an ethics committee, (2) you are designing research and want to anticipate ethical concerns before application, or (3) you are a member of an ethics committee evaluating a protocol. Even if your research seems low-risk (survey, observational study), provide a brief but clear risk-benefit assessment to demonstrate ethical reflection. For research with substantial risk (clinical trials, invasive procedures, sensitive topics), the risk-benefit section should be detailed and thoughtful.
Strengths & limitations
- Provides systematic, transparent framework for ethical judgment: instead of intuition, committees apply explicit criteria (risk minimization, reasonable ratio) enabling consistent decision-making.
- Forces honest acknowledgment of harms: researchers cannot downplay or ignore risks; formal assessment requires specification of all foreseeable harms and their magnitude.
- Protects vulnerable populations: by requiring explicit risk-benefit assessment, regulations ensure vulnerable populations (children, prisoners) are not exposed to disproportionate risks without sufficient benefit.
- Enables informed community deliberation: a clear risk-benefit statement allows non-experts (community members on ethics committees) to understand research and judge its acceptability.
- Inherent subjectivity: risk-benefit assessment is not objective; different committees may weigh the same risks and benefits differently. No 'calculator' can replace human judgment.
- Uncertainty about actual risks: at the time of ethics review, actual risks may be unknown (e.g., side effects of a novel drug). Assessment relies on preclinical data, pilot studies, and theoretical models, which may not predict real-world harms.
- Difficulty quantifying indirect benefits: 'contribution to scientific knowledge' is vague. Assessing the value of potential knowledge relative to concrete risks is inherently subjective.
- Participant versus committee perspectives may diverge: a researcher and ethics committee may judge a risk-benefit ratio differently from how a potential participant would; individuals may accept risks the committee deems unreasonable, or vice versa.
Frequently asked
Do participants have to receive direct benefits from research for it to be approved?
No. Most research offers no direct benefits to participants. In observational and survey research, participants receive no treatment or intervention. The ethics committee approves such research based on indirect benefits (advancing knowledge that may improve treatment for others). However, if risks are more than minimal or if research involves vulnerable populations, direct benefits or very substantial indirect benefits become more important to justify approval. Also, researchers cannot misrepresent the absence of direct benefits; informed consent must clearly state whether the research may directly benefit the participant.
How do I estimate the probability and magnitude of risks if they are unknown?
Use available evidence: preclinical data, literature on similar research, pilot study results, and expert opinion. For a novel intervention, review pharmacology, toxicology, and any human studies (even preliminary or in vitro). Acknowledge uncertainty explicitly in the assessment: 'Risk of serious adverse events is unknown but estimated at <5% based on animal studies.' For risks specific to the population, cite epidemiologic data: 'In the target population (ages 65+), adverse event rates in similar drugs range from 10-20%.' If a risk is genuinely unknowable, state that; the ethics committee may require monitoring for safety or a plan to halt the study if unexpected serious harms emerge.
Can I use incentives or payments to improve the risk-benefit ratio?
No. Offering participants payment does not reduce risks; risks remain the same. Payment may improve recruitment, but it does not ethically justify unreasonable risks. Additionally, if payment is so large that it constitutes 'undue inducement,' it is itself an ethical problem (it may induce people to participate despite unacceptable risks, compromising informed consent). Risk minimization and benefit justification must be grounded in research design, not compensation. Payment should be fair recompense for time and effort, not an inducement to assume risk.
What if the ethics committee thinks the risk-benefit ratio is unreasonable?
The protocol will not be approved; the ethics committee issues a 'not approved' decision. You must then either redesign the study to reduce risks (fewer procedures, less invasive, less time burden) or strengthen the benefit justification (provide more evidence for the potential importance of the research, or explain how benefits will be more directly beneficial to participants). After modification, you resubmit the protocol, typically for expedited re-review (faster than initial full-board review). If you believe the ethics committee's judgment is unreasonable, you may request to present your arguments to the full committee (an appeal); however, the committee has final authority.
Sources
- The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. (1979). The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. link ↗
- U.S. Department of Health and Human Services. (2018). Protection of Human Subjects. Code of Federal Regulations Title 45, Part 46, Section 46.102(a). link ↗
- International Council for Harmonisation. (2016). ICH Harmonised Guideline: Integrated Addendum to ICH E6(R1). Good Clinical Practice E6(R2). link ↗
- U.S. Department of Health and Human Services, Office for Human Research Protections. (2019). Risk and Benefit Assessment in Research. National Institutes of Health. link ↗
How to cite this page
ScholarGate. (2026, June 4). Systematic Evaluation of Research Risks and Benefits for Ethics Review. ScholarGate. https://scholargate.app/en/research-ethics/risk-benefit-assessment
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Clinical Trial RegistrationResearch Ethics↔ compare
- Ethics Committee Application ProcessResearch Ethics↔ compare
- Research with Vulnerable PopulationsResearch Ethics↔ compare
- Types of Ethics Committees in ResearchResearch Ethics↔ compare
- Waiver of Informed Consent in ResearchResearch Ethics↔ compare